Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4 Prostatic Neoplasms 3 Neoplasms 3 Non-Muscle Invasive Bladder Neoplasms 2 Lymphoma, B-Cell 2 Carcinoma, Transitional Cell 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Synovial 1 Pancreatic Neoplasms 1 Neoplasms, Glandular and Epithelial 1 Neoplasms by Histologic Type 1 Neoplasm, Residual 1 Lung Neoplasms 1 Liposarcoma, Myxoid 1 Leukemia, Myeloid, Acute 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Adenocarcinoma 1

Interventions

Gemcitabine 57 130-nm albumin-bound paclitaxel 35 Specimen Handling 26 Magnetic Resonance Spectroscopy 21 Albumin-Bound Paclitaxel 21 Fluorouracil 20 Leucovorin 19 Irinotecan 19 Oxaliplatin 17 Biopsy 17 Taxes 16 pembrolizumab 13 Cyclophosphamide 11 Cisplatin 11 fludarabine 10 Cetuximab 9 Capecitabine 8 Nivolumab 7 Carboplatin 7 irinotecan sucrosofate 6 durvalumab 6 dehydroftorafur 6 Radiosurgery 6 Pemetrexed 6 olaparib 5 Ipilimumab 5 Erlotinib Hydrochloride 5 trastuzumab deruxtecan 4 aldesleukin 4 Radiotherapy 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Neoplasms × ALT-803 × 90 days × Clear all

NCT07488884 2026-04-29

ResQ108B-PANC

ImmunityBio, Inc.

Phase 1 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡